Tag Archives: Antineoplastic Agents/therapeutic use

Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex

Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr. May 2014;164(5):1195-1200. Publication Date May 2014 How Analyze was Used “The volumes of the SEGAs [subependymal giant cell astrocytomas] were calculated with the use…

Vascular priming enhances chemotherapeutic efficacy against head and neck cancer

Folaron M, Kalmuk J, Lockwood J, Frangou C, Vokes J, Turowski SG, Merzianu M, Rigual NR, Sullivan-Nasca M, Kuriakose MA, Hicks WL, Jr., Singh AK, Seshadri M. Vascular priming enhances chemotherapeutic efficacy against head and neck cancer. Oral Oncol. September 2013;49(9):893-902. Full Text – Open Access Publication Date September 2013 How Analyze was Used “All…

Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis

Ungersma SE, Pacheco G, Ho C, Yee SF, Ross J, van Bruggen N, Peale FV Jr, Ross S, Carano RA. Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis. Magn Reson Med. March 2011;65(3):889-899. Full Text – Open Access* *This article corrects: Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis Vol….

Bioluminescence imaging of invasive intracranial xenografts: implications for translational research and targeted therapeutics of brain tumors

Dinca EB, Voicu RV, Ciurea AV. Bioluminescence imaging of invasive intracranial xenografts: implications for translational research and targeted therapeutics of brain tumors. Neurosurg Rev. October 2010;33(4):385-394. Publication Date October 2010 How Analyze was Used “In addition to studies correlating two imaging modalities (BLI and MRI), an alternative validation approach also found an outstanding correspondence (r2…

The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo

Seshadri M, Bellnier DA. The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo. Photochem Photobiol. January 2009;85(1):50-56. Full Text – Open Access Publication Date January 2009 How Analyze was Used “Image processing and analysis was carried out using commercially available software (Analyze PC,…

Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography

Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. September 2007;34(9):1339-1347. Publication Date September 2007 How Analyze was Used “From the summed PET image…

A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer

Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. November 2004;64(21):7995-8001. Full Text – Open Access Publication Date November 2004 How Analyze was Used “Image analysis and display was performed with Analyze 4.0 (AnalyzeDirect Inc., Lenexa,…